Chenguang Liu

Dr. Chenguang Liu

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2019 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
Ranjith KankalaRanjith Kankala
Ranjith Kankala
Hongbo ZhangHongbo Zhang
Hongbo Zhang
CLChenguang Liu
Chenguang Liu
KKKiran Reddy Kanubaddi
Kiran Reddy Kanubaddi
CLChia‐Hung Lee
Chia‐Hung Lee
ACAi-Zheng Chen
Ai-Zheng Chen

1 March 2020 in Chemical Engineering Journal
Verified
Journal Article
Closed access
Ranjith KankalaRanjith Kankala
Ranjith Kankala
CLChenguang Liu
Chenguang Liu
DYDa-Yun Yang
Da-Yun Yang
SWShi-Bin Wang
Shi-Bin Wang
ACAi-Zheng Chen
Ai-Zheng Chen

22 September 2017 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
Ranjith KankalaRanjith Kankala
Ranjith Kankala
CLChenguang Liu
Chenguang Liu
ACAi-Zheng Chen
Ai-Zheng Chen
SWShi-Bin Wang
Shi-Bin Wang
PXPei-Yao Xu
Pei-Yao Xu
YHYu-Fang Hu
Yu-Fang Hu

1 February 2020 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
CLChenguang Liu
Chenguang Liu
YHYa-Hui Han
Ya-Hui Han
Ranjith KankalaRanjith Kankala
Ranjith Kankala
SWShi-Bin Wang
Shi-Bin Wang
ACAi-Zheng Chen
Ai-Zheng Chen
With the advent of nanotechnology, various modes of traditional treatment strategies have been transformed extensively owing to the advantageous morphological, physiochemical, and functional attributes of nano-sized materials, which are of particular interest in diverse biomedical applications, such as diagnostics, sensing, imaging, and drug delivery. Despite their success in delivering therapeutic agents, several traditional nanocarriers often end up with deprived selectivity and undesired therapeutic outcome, which significantly limit their clinical applicability. Further advancements in terms of improved selectivity to exhibit desired therapeutic outcome toward ablating cancer cells have been predominantly made focusing on the precise entry of nanoparticles into tumor cells via targeting ligands, and subsequent delivery of therapeutic cargo in response to specific biological or external stimuli. However, there is enough room intracellularly, where diverse small-sized nanomaterials can accumulate and significantly exert potentially specific mechanisms of antitumor effects toward activation of precise cancer cell death pathways that can be explored. In this review, we aim to summarize the intracellular pathways of nanoparticles, highlighting the principles and state of their destructive effects in the subcellular structures as well as the current limitations of conventional therapeutic approaches. Next, we give an overview of subcellular performances and the fate of internalized nanoparticles under various organelle circumstances, particularly endosome or lysosome, mitochondria, nucleus, endoplasmic reticulum, and Golgi apparatus, by comprehensively emphasizing the unique mechanisms with a series of interesting reports. Moreover, intracellular transformation of the internalized nanoparticles, prominent outcome and potential affluence of these interdependent subcellular components in cancer therapy are emphasized. Finally, we conclude with perspectives with a focus on the contemporary challenges in their clinical applicability.

1 August 2019 in Chemical Engineering Journal
Verified
Journal Article
Closed access
CLChenguang Liu
Chenguang Liu
YHYa-Hui Han
Ya-Hui Han
JZJian-Ting Zhang
Jian-Ting Zhang
Ranjith KankalaRanjith Kankala
Ranjith Kankala
SWShi-Bin Wang
Shi-Bin Wang
ACAi-Zheng Chen
Ai-Zheng Chen

8 May 2019 in Small
Verified
Journal Article
Closed access
PDF file
Ranjith KankalaRanjith Kankala
Ranjith Kankala
JZJia Zhao
Jia Zhao
CLChenguang Liu
Chenguang Liu
XSXiao‐Jie Song
Xiao‐Jie Song
DYDa‐Yun Yang
Da‐Yun Yang
ACAi-Zheng Chen
Ai-Zheng Chen